Europe’s biotech ecosystem is broken at the ends

07/07/2026

Europe’s biotech ecosystem is broken at the ends The middle holds. The ends are collapsing. Fresh startups and near-commercial firms are strained and cannot access capital in EU. Without more qualified early-stage funding now, there will be no mature EU biotech...

MinvervaX CFO & CDO Appointment

19/04/2026

MinvervaX CFO & CDO Appointment MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), today announces the appointments of Jamila Louahed as Chief Development Officer and Hans...

Is biotech venture capital investing more to return less?

12/02/2026

At Sunstone we continue to track risk-adjusted return multiples (adjusted for contingent payments) versus the total capital invested in private therapeutic companies prior to M&A exits. When looking at the median trends over the past 15 years, the inflection...

An update on M&A returns for biotech venture capital

28/01/2026

Back in in 2019 Sunstone started sharing studies of European venture capital funded successes – i.e. M&A transactions. In 2021 we started adding US M&A’s to the data and later the same year we evaluated to which extent an IPO impacted the observations made....